Aflibercept 8 mg late-breaking data presented at retina society in diabetic macular edema and wet age-related macular degeneration

Presentations reinforce that aflibercept 8 mg demonstrated non-inferior vision gains to eylea at 48 weeks, with 93% and 83% of patients in photon and pulsar, respectively, maintaining dosing intervals of 12 weeks or longer after initial monthly doses additional new pre-specified and exploratory analyses showed aflibercept 8 mg led to sustained improvements in certain anatomical measures during the 48-week treatment period for both 12- and 16-week dosing regimens in photon and pulsar tarrytown, n.y. , nov. 4, 2022 /prnewswire/ -- regeneron pharmaceuticals, inc. (nasdaq: regn) today announced late-breaking presentations of updated results from two positive pivotal trials investigating novel aflibercept 8 mg with 12- and 16-week dosing regimens, compared to eylea® (aflibercept) injection, in patients with diabetic macular edema (dme) and wet age-related macular degeneration (wamd).
REGN Ratings Summary
REGN Quant Ranking